These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 9242460

  • 1. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
    Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J.
    Cancer Res; 1997 Aug 01; 57(15):3272-80. PubMed ID: 9242460
    [Abstract] [Full Text] [Related]

  • 2. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
    Cancer J Sci Am; 1997 Aug 01; 3(1):21-30. PubMed ID: 9072304
    [Abstract] [Full Text] [Related]

  • 3. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
    Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK.
    Gynecol Oncol; 2005 Nov 01; 99(2):415-21. PubMed ID: 16157365
    [Abstract] [Full Text] [Related]

  • 4. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU, Wallasch C, Campiglio M, Issing W, Ullrich A.
    J Cell Physiol; 1997 Nov 01; 173(2):187-95. PubMed ID: 9365520
    [Abstract] [Full Text] [Related]

  • 5. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma.
    Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, Kelly P, Pearson AD, Lunec J.
    Cancer Res; 1998 Sep 01; 58(17):3932-41. PubMed ID: 9731505
    [Abstract] [Full Text] [Related]

  • 6. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
    Clin Cancer Res; 2005 Mar 15; 11(6):2163-8. PubMed ID: 15788662
    [Abstract] [Full Text] [Related]

  • 7. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A.
    Int J Oncol; 2008 Jul 15; 33(1):195-204. PubMed ID: 18575766
    [Abstract] [Full Text] [Related]

  • 8. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R.
    Oncogene; 1999 Jan 14; 18(2):305-14. PubMed ID: 9927187
    [Abstract] [Full Text] [Related]

  • 9. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.
    Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S.
    Nature; 1993 Dec 02; 366(6454):473-5. PubMed ID: 7902537
    [Abstract] [Full Text] [Related]

  • 10. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA.
    J Clin Oncol; 2011 Aug 01; 29(22):3030-6. PubMed ID: 21709195
    [Abstract] [Full Text] [Related]

  • 11. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.
    De Potter IY, Poumay Y, Squillace KA, Pittelkow MR.
    Exp Cell Res; 2001 Dec 10; 271(2):315-28. PubMed ID: 11716544
    [Abstract] [Full Text] [Related]

  • 12. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
    Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP.
    Cancer; 2005 Dec 15; 104(12):2701-8. PubMed ID: 16265675
    [Abstract] [Full Text] [Related]

  • 13. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.
    Crit Rev Oncol Hematol; 2010 May 15; 74(2):73-8. PubMed ID: 19481955
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors.
    Bodey B, Kaiser HE, Siegel SE.
    In Vivo; 2005 May 15; 19(5):931-41. PubMed ID: 16097449
    [Abstract] [Full Text] [Related]

  • 15. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
    Campiglio M, Ali S, Knyazev PG, Ullrich A.
    J Cell Biochem; 1999 Jun 15; 73(4):522-32. PubMed ID: 10733345
    [Abstract] [Full Text] [Related]

  • 16. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
    Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, Henriksson R.
    Acta Neuropathol; 2004 Aug 27; 108(2):135-42. PubMed ID: 15148612
    [Abstract] [Full Text] [Related]

  • 18. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma VM.
    Eur J Cancer; 2004 Jul 27; 40(10):1485-95. PubMed ID: 15196531
    [Abstract] [Full Text] [Related]

  • 19. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD, Antoniucci DM, Fok KS, Alajoki ML, Harkins RN, Thompson SA, Wada HG.
    J Biol Chem; 1995 Sep 22; 270(38):22608-13. PubMed ID: 7673253
    [Abstract] [Full Text] [Related]

  • 20. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.
    J Pathol; 2003 Jul 22; 200(3):290-7. PubMed ID: 12845624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.